Sildenafil (Viagra / Revatio)

Overview / What Is It

Sildenafil citrate (brand: Viagra for ED, Revatio for pulmonary arterial hypertension) was the first selective PDE5 inhibitor approved by the FDA, receiving approval in 1998. Originally developed by Pfizer as a cardiovascular agent for angina pectoris (cardiac chest pain), its vasodilatory effects in penile smooth muscle were discovered during Phase 1 clinical trials — one of pharmacology's most fortuitous serendipitous discoveries. Sildenafil at 20mg three times daily (as Revatio) is an FDA-approved treatment for PAH.

Compared to tadalafil (17.5-hour half-life) and avanafil (1.3-hour half-life), sildenafil occupies the middle ground with a ~4-hour half-life — enabling on-demand dosing without the 36-hour duration of tadalafil but providing longer activity than avanafil. This makes sildenafil the most studied PDE5 inhibitor with the largest clinical trial database, but also the one most significantly affected by food co-ingestion — high-fat meals delay peak plasma concentration by up to 60–120 minutes and reduce Cmax by ~30%.

Research interest in the AAS context parallels tadalafil's: sildenafil's endothelial function improvements (flow-mediated dilation, NO bioavailability), blood pressure reduction, and pulmonary vasodilation all address known consequences of chronic AAS use. The distinction versus tadalafil is primarily in half-life (on-demand vs daily), absence of PDE11 inhibition (no back pain/myalgia side effect), and superior selectivity for PDE5 over other PDE isoforms.

Mechanism of Action

Core PDE5 pathway (identical to tadalafil): Nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) activates guanylate cyclase, converting GTP to cyclic GMP (cGMP) in smooth muscle cells. cGMP causes smooth muscle relaxation and vasodilation. PDE5 degrades cGMP, terminating vasodilation. Sildenafil selectively and competitively inhibits PDE5, preventing cGMP breakdown and sustaining vasodilation.

PDE selectivity profile: Sildenafil is 4,000× more selective for PDE5 vs PDE3 (cardiac isoform — the pharmacological target of concern for cardiovascular safety) and approximately 10× more selective for PDE5 vs PDE6 (retinal phosphodiesterase). PDE6 cross-reactivity is why approximately 3% of sildenafil users experience transient blue-tinged vision or increased light sensitivity — a recognized side effect that does not occur with tadalafil (more PDE5-selective). Sildenafil has minimal PDE11 activity, explaining the absence of the back pain/myalgia unique to tadalafil.

Cardiovascular endothelial effects: Sildenafil improves flow-mediated dilation (FMD) of the brachial artery — a validated surrogate measure of endothelial function. Research in subjects with erectile dysfunction and coronary artery disease (populations with overlapping endothelial dysfunction to AAS-using subjects) shows FMD improvements of 30–50% with chronic sildenafil. Sildenafil reduces mean arterial pressure by approximately 8–10 mmHg systolic when used as a cardiovascular adjunct.

Pulmonary vascular selectivity (Revatio): At Revatio doses (20mg TID), sildenafil produces substantial pulmonary vasodilation — reducing pulmonary vascular resistance (PVR) by 20–30% and improving 6-minute walk distance in PAH. The pulmonary selectivity occurs because pulmonary smooth muscle is rich in PDE5, and sildenafil is administered before the patient's peak metabolic demand, accumulating in pulmonary tissue over time with TID dosing.

Clinical Protocol Context

Sildenafil is the original PDE5 inhibitor and one of the most extensively studied cardiovascular-active drugs in modern medicine. The landmark Goldstein et al. (1998, NEJM) trial established efficacy for erectile dysfunction across etiologies. The SUPER-1 trial (Galiè et al., 2005, NEJM) demonstrated significant improvement in exercise capacity in pulmonary arterial hypertension at 20 mg TID. Cardiovascular safety data from Arruda-Olson et al. (2002) and the absolute nitrate contraindication remain critical protocol considerations.

Dosing & Administration

ED indication (on-demand): 50mg taken 30–60 minutes before anticipated activity. Titrate: 25mg (inadequate response to 50mg causing intolerable side effects) or 100mg (inadequate response at 50mg). Maximum: 100mg per 24-hour period. Duration of effect: 4–6 hours. Food significantly affects onset — high-fat meals delay Tmax by 60–120 minutes. For reliable timing, administer on an empty stomach or with a light meal.

Pulmonary arterial hypertension (Revatio): 20mg three times daily, approximately 4–6 hours apart. This TID schedule maintains continuous pulmonary PDE5 inhibition given the 4-hour half-life. Higher doses (40mg, 80mg TID) were studied and showed no additional benefit for 6MWT, with increased adverse effects — the 20mg TID dose is the established therapeutic exposure for PAH.

Cardiovascular/endothelial research context: Most cardiovascular research uses 50–100mg on-demand. Daily low-dose protocols (25–50mg daily) have been studied for endothelial function, with FMD improvements documented at 25mg. Unlike tadalafil where 5mg daily is the established low-dose maintenance protocol, sildenafil's shorter half-life makes consistent daily low-dose protocols pharmacokinetically less elegant — plasma concentrations fluctuate significantly between doses.

Renal and hepatic dose adjustment: Severe renal impairment (CrCl <30 mL/min): starting dose 25mg. Hepatic impairment (Child-Pugh A or B): starting dose 25mg due to reduced clearance. Avoid in severe hepatic impairment.

Food interaction (clinically important difference from tadalafil): High-fat meals reduce Cmax by ~29% and delay Tmax by ~60 minutes. For on-demand use, administer 1 hour before activity on an empty stomach, or at least 2 hours post-high-fat meal. This food interaction is absent with tadalafil — a practical advantage of tadalafil for research subjects with unpredictable meal timing.

Bloodwork & Monitoring

• Blood pressure (primary): Baseline and recheck at 2 weeks. Sildenafil reduces systolic BP by 8–10 mmHg / diastolic by 5–6 mmHg. The effect is additive with antihypertensives — orthostatic hypotension risk is most pronounced when standing rapidly. Monitor lying and standing BP in the first weeks of co-administration with any antihypertensive agent.
• Lipid panel and hematocrit (AAS context): Cardiovascular risk stratification for subjects co-using AAS. LDL, HDL, TG, total cholesterol — AAS-induced dyslipidemia amplifies endothelial dysfunction burden. Hematocrit target <52% — erythrocytosis elevates blood viscosity and compounds hypertension risk in subjects adding a vasodilating agent.
• Vision monitoring (subjective): Blue-tinged vision or increased light sensitivity (PDE6-mediated) — self-reported at first dose. Resolves rapidly with drug clearance. If persistent beyond 6 hours or associated with vision loss, stop immediately and seek evaluation. NAION (non-arteritic anterior ischemic optic neuropathy) association is the same as with tadalafil — sudden unilateral vision loss requires emergent ophthalmological evaluation.
• Liver function (Revatio/PAH doses only): At the higher Revatio dosing (20mg TID = 60mg/day cumulative), hepatic monitoring is more relevant than at ED dosing. ALT, AST, ALP at baseline and 3-month intervals for subjects on continuous PAH dosing. Not routinely required for on-demand ED dosing in healthy subjects.
• Pulmonary arterial hypertension subjects: 6-minute walk test for functional capacity monitoring. Right heart catheterization (mPAP, PVR, CO) at specialist centers for hemodynamic response assessment. NT-proBNP as a PAH severity biomarker — reduction with treatment predicts long-term outcomes.

Side Effects & Risk Profile

Common (PDE5-mediated vasodilation): Headache (11–16% incidence — most common adverse effect, cerebral vasodilation), flushing (10% — facial/neck/chest warmth), nasal congestion (4%), dyspepsia (gastric reflux via lower esophageal sphincter smooth muscle relaxation). These effects are dose-dependent and typically mild to moderate in severity.

Visual disturbances (PDE6 inhibition — sildenafil-specific): Blue-tinged or blue-green color tinge to vision, increased sensitivity to light, blurred vision — reported in approximately 3% of users at 50mg, increasing dose-dependently to ~11% at 100mg. PDE6 is the retinal cyclic GMP phosphodiesterase; its inhibition by sildenafil (not tadalafil, which is more PDE5-selective) produces these transient visual effects. Typically onset at 1–2 hours post-dose, resolves within 6 hours as sildenafil clears. Not associated with structural retinal damage at standard doses.

Cardiovascular — primary serious risk: Hypotension — the pharmacodynamic consequence of vasodilation, amplified by nitrates (absolute contraindication), alpha-blockers, and antihypertensives. Priapism (prolonged erection >4 hours) — rare urological emergency requiring immediate intervention; permanent erectile dysfunction can result without prompt treatment.

NAION (rare, serious): Non-arteritic anterior ischemic optic neuropathy — sudden unilateral vision loss due to optic nerve ischemia. FDA black box warning. Risk factors: pre-existing optic disc abnormality ("disc-at-risk"), history of cardiovascular disease, low cup-to-disc ratio. Any sudden vision change: stop immediately and seek ophthalmological evaluation within hours.

Sudden hearing loss (rare): Sudden sensorineural hearing loss — rare, unilateral. Mechanism unclear; may be vascular. Stop and seek audiological evaluation if onset during use.

Drug Interactions

• Alpha-blockers (tamsulosin, doxazosin, terazosin): Significant additive hypotension. For sildenafil on-demand dosing: wait at least 4 hours after tamsulosin administration. For non-selective alpha-blockers (doxazosin): avoid combination or initiate at lowest dose with standing BP monitoring. The combination is used clinically in BPH management under specialist supervision.
• CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin): Ritonavir increases sildenafil AUC 11-fold — maximum sildenafil dose 25mg every 48 hours with ritonavir. Other strong CYP3A4 inhibitors: reduce dose to 25mg and monitor. Grapefruit juice: moderate CYP3A4 inhibition, unpredictable plasma exposure increase.
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort): Substantially reduce sildenafil plasma concentrations, potentially eliminating therapeutic effect. Avoid combination.
• Antihypertensives (amlodipine, lisinopril, telmisartan): Additive BP reduction. The combination is used intentionally for cardiovascular risk management in AAS research contexts. Monitor orthostatic BP — lying-to-standing BP drop. Start antihypertensive at lowest dose if adding to stable sildenafil.
• Tadalafil / other PDE5 inhibitors: Do not combine. Additive PDE5 inhibition produces additive vasodilation and hypotension without additional benefit. Research protocols must not include concurrent PDE5 inhibitor use.
• Alcohol: Additive vasodilation. Heavy alcohol co-ingestion significantly amplifies flushing, headache, and hypotensive symptoms. Research subjects should avoid significant alcohol during sildenafil use.
• AAS (testosterone, anabolic steroids): No direct pharmacokinetic interaction. AAS-induced endothelial dysfunction is the mechanistic rationale for sildenafil co-use in research protocols. No dose adjustment based on AAS co-administration. Monitor BP — AAS-induced hypertension and sildenafil vasodilation require combined cardiovascular assessment.

Harm Reduction

• Nitrate rule is absolute. Recreational nitrate inhalants (poppers — amyl nitrite, butyl nitrite) are used in sexual contexts and are frequently co-ingested with sildenafil. This combination has produced cardiovascular deaths. The contraindication applies equally to prescription nitrates (nitroglycerin patches, sublingual tabs) and recreational nitrites. There is no safe interval.
• Take on an empty stomach or light meal for reliable onset timing. High-fat food significantly delays and reduces peak plasma concentration — research protocols with time-sensitive endpoints must account for this food interaction (which does not affect tadalafil).
• Any sudden vision change, even mild blue tinge or unusual color perception, may indicate the beginning of a serious ocular event. Stop sildenafil and seek ophthalmological evaluation within hours if vision changes are persistent or associated with dimming rather than just color distortion.
• Priapism (>4-hour erection): urological emergency. Seek immediate emergency care. Do not wait — irreversible corporal damage begins after 4–6 hours of ischemic priapism. Risk is elevated in sickle cell disease, multiple myeloma, and polycythemia — hematological conditions that overlap with AAS-induced erythrocytosis.
• In AAS research subjects with elevated hematocrit (>50%), monitor blood pressure carefully. Erythrocytosis increases blood viscosity and systemic vascular resistance — sildenafil's vasodilation counteracts this, but the combination can produce unpredictable orthostatic hypotension responses.
• Do not exceed 100mg per 24 hours. No clinical benefit is demonstrated above 100mg and adverse effect burden increases substantially. Research subjects who report inadequate response to 100mg should be evaluated for confounding factors (food interaction, timing) rather than dose escalation.

Research & Literature

Original PAH trial (SUPER-1): Galiè et al. (NEJM 2005) — the pivotal Phase 3 RCT establishing sildenafil 20/40/80mg TID for PAH. The 20mg TID dose was selected for approval based on equivalent efficacy to higher doses with superior tolerability: 45-meter improvement in 6-minute walk distance (6MWD) vs placebo. This study led to FDA approval of Revatio for PAH.

Endothelial function in cardiovascular disease: Halcox et al. (Circulation 2002) demonstrated sildenafil improved coronary endothelial dysfunction in subjects with atherosclerosis and normal coronary angiograms — the same mechanism relevant to AAS-induced endothelial pathology. Katz et al. (JACC 2000) showed sildenafil improved exercise tolerance and FMD in stable coronary artery disease subjects.

AAS-induced endothelial dysfunction context: Kasikcioglu et al. (Int J Cardiol 2007) documented severely impaired FMD in AAS-using athletes — the same biomarker Sildenafil/Tadalafil research uses as its primary endpoint, establishing the mechanistic rationale for PDE5 inhibitor research in AAS users. AAS-induced endothelial dysfunction is now recognized as a significant long-term cardiovascular risk factor (Baggish et al., Circulation 2010; Rasmussen et al., JAHA 2021).

Pharmacokinetics and food interaction: Muirhead et al. (BJC Pharmacol 2002) characterized the high-fat meal effect on sildenafil: 29% reduction in Cmax, 60-minute Tmax delay — establishing the clinical importance of fasted administration for predictable pharmacokinetics. This paper is why sildenafil package inserts specify empty-stomach dosing for on-demand use.

Comparative PDE5 inhibitor studies: Donatucci et al. (J Sex Med 2011) compared sildenafil vs tadalafil head-to-head — similar efficacy at matched doses, with tadalafil preferred for daily dosing convenience and absence of PDE6 visual side effects, sildenafil preferred for subjects requiring shorter duration of action. Porst et al. (Eur Urol 2003) meta-analysis established the comparable efficacy across the PDE5 inhibitor class.